Cargando…
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
Attempts to elicit antibodies with potent neutralizing activity against a broad range of human immunodeficiency virus (HIV) isolates have so far proven unsuccessful. Long-term delivery of monoclonal antibodies (mAbs) with such activity is a creative alternative that circumvents the need for an immun...
Autores principales: | Fuchs, Sebastian P, Desrosiers, Ronald C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289440/ https://www.ncbi.nlm.nih.gov/pubmed/28197421 http://dx.doi.org/10.1038/mtm.2016.68 |
Ejemplares similares
-
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020) -
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
por: Fuchs, Sebastian P., et al.
Publicado: (2016) -
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
por: Gardner, Matthew R., et al.
Publicado: (2019) -
Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
por: Termini, James M., et al.
Publicado: (2020) -
Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys
por: Fuchs, Sebastian P., et al.
Publicado: (2019)